FDA Advisers Urge More Data On Paxlovid To Ease Concerns Of Rebound

Several members of FDA’s antimicrobial drugs advisory committee are concerned that fear of COVID-19 rebound is causing many doctors and patients to not prescribe or take Pfizer’s coronavirus drug Paxlovid, and they said more data could help bolster already-existing evidence that the drug is not associated with the resurgence of disease in patients who have already been treated with Paxlovid. The discussion was part of a Thursday (March 16) meeting of FDA’s Antimicrobial Drugs Advisory Committee during which the panel...